glp-1 obesity drug news today 2025-10-20 Perspectives from employers on the costs and issues associated with covering agonists for weight loss Cigna drops coverage of GLP-1

Seven drugs have currently been approved for the treatment of Type 2 diabetes mellitus, including short-acting agents like exenatide and lixisenatide, as well as long-acting injectable agents such as albiglutide, dulaglutide, liraglutide, and semaglutide. GLP-1s regulate lipid metabolism, reducing the effects of hyperlipidemia and helping to lower the risk for both chronic kidney disease (CKD) and diabetic kidney disease. They have also been shown to reduce oxidative stress, which includes stimulating glomerular filtration and reducing vasoconstriction, slowing the progression of CKD. Limited data from clinical trials have been published on the effects of GLP-1 receptor agonists in individuals with post-liver transplant diabetes mellitus (PTDM)

He joined Bill Brodsky and Elliott Ingerman as a partner at Tribeca Associates

Related products NBL Natural Saw Palmetto Extract 320 mg with Pumpkin Seed Oil, 90 Softgels Acidophilus Probiotic Digestive Health Vitamin C 1000 mg, Sustained Release with Rose Hip, Antioxidant Protection* NBL Natural Hydrolysed Marine Collagen 2500mg with Hyaluronic Acid, Resveratrol, Biotin, Selenium & Vitamin C, 120 Tablets

Its antioxidant properties support brain cell health and function

It strengthens their nutraceutical and cardiac wellness portfolio